Doubled survival in metastatic lung cancer with combination therapy
Doubled survival in metastatic lung cancer with combination therapy
Combined immuno-chemotherapy improves survival and responses in metastatic lung cancer
Results from CheckMate-227 : Immune combination reaches PFS endpoint
Editor's Choice for February 2018
Integrative analyses to identify genetic determinants of immune responsiveness in cancer
Immuno-oncology in breast and cervical cancer
Expert insight: Managing neutropenia in breast cancer patients
Approaches to screening and early detection across Europe
Cancer Core Europe
Roche joining forces to forward precision oncology
Phase III trial data supports current standard 12-month adjuvant trastuzumab for HER2-positive breast cancer
Immunotherapy shows early promise for patients with trastuzumab-resistant breast cancer